Indianapolis-based Eli Lilly and Co. (NYSE: LLY) is reporting second quarter net income of $1.3 billion, compared to $1.4 billion during the same period last year. Chief Executive Officer David Ricks says the company’s performance was due to volume-driven growth across its core business and most major geographies.
“We accelerated use of our newest medicines around the world with solid sequential growth versus first-quarter 2021,” said Ricks. “We had another robust period of pipeline milestones, as we announced plans to submit tirzepatide in type 2 diabetes and donanemab in Alzheimer’s disease to regulatory authorities later this year, as well as positive results for Jardiance in patients with heart failure with preserved ejection fraction. We continue to increase investment in our future and look forward to several additional pipeline events in the second half of the year, along with the continued strengthening of our business.”
You can connect to the full earnings report by clicking here.